Table 1 Comparison of clinical variables between SLE patients and healthy controls
Variable | SLE n = 196 | Healthy Controls n = 52 | p |
|---|---|---|---|
Age (years) a | 45 (18–73) | 47 (22–54) | 0.87 |
Gender b | 196 (100) | 52 (100) | – |
Mexican-Mestizo b | 196 (100) | 52 (100) | – |
BMI (kg/m2) a | 27.3 (17.7–40.0) | 27.9 (18.4–47.3) | 0.86 |
SLE duration (years) a | 8.3 (2–28) | – | – |
C3 fraction complement (mg/dL) a | 142.0 (42.0–252.0) | – | – |
C4 fraction complement (mg/dL) a | 31 (6.6–71.7) | – | – |
Positive anti-dsDNA b | 55 (28.1) | – | – |
SLEDAI (score) a | 2 (0–12) | – | – |
rSLEDAI (score) a | 0 (0–12) | – | – |
- Renal-SLE patients b | 43 (21.9) | – | – |
SLICC/ACR (score) a | 1 (0–5) | – | – |
MEX-SLEDAI (score) a | 1 (0–10) | – | – |
Glucocorticoids b | 196 (100) | – | – |
- Prednisone > 10 mg/day b | 60 (30.6) | – | – |
Immunosuppressive drugs b | 145 (74.0) | – | – |
- Azathioprine users b | 91 (46.4) | – | – |
- Cyclophosphamide users b | 13 (6.6) | – | – |
- Mycophenolate users b | 56 (28.5) | – | – |
Other drugs (Methotrexate) b | 27 (13.8) |